Overview

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Status:
Completed

Trial end date:
2020-01-31

Target enrollment:

Participant gender:

Summary

To assess the safety and efficacy of repeated intravitreal injections of DE-122 (low dose and high dose) given in combination with Lucentis® in subjects with wet age-related macular degeneration (AMD) compared with Lucentis® alone.

Phase:

Phase 2

Details

Lead Sponsor:

Santen Inc.

Treatments:

Pharmaceutical Solutions
Ranibizumab